The Reckitt Benckiser share price falls after sales leap. Do I buy Reckitt?

Despite decent quarterly sales growth, the Reckitt Benckiser share price is falling. But Reckitt is on a journey and there may be value in RKT stock.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

UK consumer-goods giant Reckitt Benckiser (LSE: RKT) released its first-quarter results yesterday morning. Unfortunately, despite sales growth continuing into 2021, the Reckitt Benckiser share price slid again.

Down goes the Reckitt Benckiser share price

On Tuesday, the Reckitt Benckiser share price closed at 6,586p (almost £66). However, following the results announcement on Wednesday, the stock headed south right from the off. After falling early morning, the shares continued to decline all day. At its low yesterday, the share price dipped to a low of 6,315p, before inching up to close at 6,328p. That marked a fall of 258p, down 3.9%.

What caused the Reckitt Benckiser share price to fall on Wednesday? After all, Reckitt beat sales forecasts, thanks to booming sales of hygiene products used to fight Covid-19. Like-for-like revenues were up 4.1%, ahead of predictions. However, this was well below the 13.3% growth recorded a year ago as Covid-19 infections exploded last spring. Somewhat predictably, sales of Lysol disinfectant and the like surged, with sales of hygiene products soaring by 28.5%.

However, Reckitt took a hit as its health (sales -13%) and nutrition (-7.4%) divisions failed to live up to expectations. With most of the world masked up and in lockdown, cold and flu infections plummeted. This caused a drop of nine-tenths (90%) in sales of medicines such as Mucinex, Nurofen, and Strepsils. Nevertheless, total net revenue topped £3.5bn, while ecommerce sales rose by almost a quarter (24%) to more than an eighth (13%) of total revenues. So why the weak share price?

Reckitt ditches its RB brand

In 2009, Reckitt Benckiser launched a major rebrand as RB, introducing a new logo and dropping its historic monikers. Twelve years later, it has admitted defeat and, last month, it decided to be known as…Reckitt. With another new logo and market ticker (RKT). For a company with origins dating back 207 years to 1814, this branding blather is a waste of management time and effort. Meanwhile, the Slough-based business is aiming to expand through four growth drivers: increased penetration, market share gains, new places, and new spaces. Perhaps this expansion of its customers, product ranges, and markets will help boost the Reckitt Benckiser share price in future?

Would I buy Reckitt today?

1W -6.7%
1M -3.6%
3M 0.4%
6M -7.7%
1Y -2.0%
2Y 2.3%
3Y 14.0%
5Y -6.3%

As you can see, the

At the current

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Cliffdarcy has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »